Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
Items 401–500 of 1,007
Louie, S., Haley, B., Marshall, B., Heidersbach, A. J., Yim, M., Brozynski, M., Tang, D., Lam, C., Petryniak, B., Shaw, D., et al. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26188 · Cited by 55
Towards a new avenue for producing therapeutic proteins: Microalgae as a tempting green biofactory
Dehghani, J., Adibkia, K., Movafeghi, A., Maleki, H., Saeedi, N., & Omidi, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107499 · Cited by 51
Lohse, S., Brunke, C., Derer, S., Peipp, M., Boross, P., Kellner, C., Beyer, T., Dechant, M., van de Winkel, J. G. J., Leusen, J. H. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353060 · Cited by 51
“terminal non-sialylated galactose, (1,6)-linked fucose, -linked mannose, N-acetylglucosamin, and human -chain were detected for wild type and mutant”
BackgroundInfluentialNG, S., Wang, D. I. C., & YAP, M. (2007) · Metabolic Engineering · doi:10.1016/j.ymben.2007.01.001 · Cited by 55
Influence of pluronic F68 on oxygen mass transfer
Sieblist, C., Jenzsch, M., & Pohlscheidt, M. (2013) · Biotechnology progress (Print) · doi:10.1002/btpr.1770 · Cited by 53
Bhut, B. V., Christensen, K., & Husson, S. M. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.05.049 · Cited by 51
Protein Glycosylation and Its Impact on Biotechnology
Berger, M., Kaup, M., & Blanchard, V. (2011) · Springer eBooks · doi:10.1007/10_2011_101 · Cited by 57
Attenuating apoptosis in Chinese hamster ovary cells for improved biopharmaceutical production
Henry, M. N., MacDonald, M. A., Orellana, C. A., Gray, P. P., Gillard, M., Baker, K. N., Nielsen, L. K., Marcellin, E., Mahler, S. M., & Martínez, V. S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27269 · Cited by 54
“…production cell line in the biopharmaceutical industry due to their robustness, scalability, ability to generate human-like post-translational modifications, and proven regulatory track record (Jayapal, Wlaschin, Hu, & Yap, 2007; Matasci, Hacker, Baldi, & Wurm, 2009; Walsh, 2010; Wurm, 2004).”
High Throughput and Highly Controllable Methods for In Vitro Intracellular Delivery
Brooks, J. R., Minnick, G., Mukherjee, P., Jaberi, A., Chang, L., Espinosa, H. D., & Yang, R. (2020) · Small · doi:10.1002/smll.202004917 · Cited by 54
Continuous Biopharmaceutical Processes: Chromatography, Bioconjugation, and Protein Stability
Pfister, D., Nicoud, L., & Morbidelli, M. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108332897 · Cited by 57
Naderi, S., Meshram, M., Wei, C., McConkey, B., Ingalls, B., Budman, H., & Scharer, J. (2011) · Biotechnology Progress · doi:10.1002/btpr.647 · Cited by 49
Production of chimeric monoclonal antibodies by genetically manipulated chickens
Kamihira, M., Kawabe, Y., Shindo, T., Ono, K.-I., Esaka, K., Yamashita, T., Nishijima, K.-I., & Iijima, S. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.02.022 · Cited by 51
Das, D., & Goyal, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8005-1_15 · Cited by 51
Schiedner, G., Hertel, S., Bialek, C., Kewes, H., Waschütza, G., & Volpers, C. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-13 · Cited by 50
“Expression levels of the protein of interest depend on numerous factors including the promoter, cellular levels of relevant transcription factors, presence of factors transactivating the promoter, the number of gene copies within the cell and the chromatin structure at the integration site [11].”
BackgroundEibl, R., & Eibl, D. (2009) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2008_23 · Cited by 57
Dorai, H., Santiago, A., Campbell, M., Tang, Q. M., Lewis, M. J., Wang, Y., Lu, Q., Wu, S., & Hancock, W. S. (2010) · Biotechnology Progress · doi:10.1002/btpr.537 · Cited by 50
“The majority of therapeutic proteins are being produced in mammalian cell culture systems or in Escherichia coli (reviewed in Walsh, 2005; Wurm, 2004).”
BackgroundSingle cell screening approaches for antibody discovery
Fitzgerald, V., & Leonard, P. (2016) · Methods · doi:10.1016/j.ymeth.2016.11.006 · Cited by 51
Monoclonal Cell Line Generation and CRISPR/Cas9 Manipulation via Single‐Cell Electroporation
Yang, R., Lemaître, V., Huang, C., Haddadi, A., McNaughton, R. L., & Espinosa, H. D. (2018) · Small · doi:10.1002/smll.201702495 · Cited by 54
Sieblist, C., Jenzsch, M., & Pohlscheidt, M. (2015) · Cytotechnology · doi:10.1007/s10616-015-9899-0 · Cited by 51
“Due to their ability to properly glycosylate and process these complex large molecules, mammalian cells in suspension are the expression system of choice in the industry (Qi et al. 2003; Sethuraman and Stadheim 2006; Wurm 2004; Xie and Wang 1997).”
BackgroundSerum-free production and purification of chimeric IgA antibodies
Beyer, T. D., Lohse, S., Berger, S., Peipp, M., Valerius, T., & Dechant, M. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.05.002 · Cited by 49
Lim, U.-M., Yap, M. G. S., Lim, Y. P., Goh, L., & Ng, S. K. (2013) · Journal of Proteome Research · doi:10.1021/pr400352n · Cited by 54
Sellhorn, G., Caldwell, Z., Mineart, C., & Stamatatos, L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.028 · Cited by 50
Reuel, N. F., Grassbaugh, B. R., Kruss, S., Mundy, J. Z., Opel, C. F., Ogunniyi, A. O., Egodage, K. L., Wahl, R., Helk, B., Zhang, J., et al. (2013) · ACS Nano · doi:10.1021/nn403215e · Cited by 51
Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies
Gefroh, E., Dehghani, H., McClure, M., Connell‐Crowley, L., & Vedantham, G. (2014) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2014.00978 · Cited by 51
“Chinese hamster ovary (CHO) cells are widely used cell substrates for production of recombinant protein therapeutics (30).”
BackgroundImmunogenomic engineering of a plug-and-(dis)play hybridoma platform
Pogson, M., Parola, C., Kelton, W. J., Heuberger, P., & Reddy, S. T. (2016) · Nature Communications · doi:10.1038/ncomms12535 · Cited by 50
“This means several months and up to 1 year are typically required before the selection of an optimal stable clone 10 .”
Chung, C., Wang, Q., Yang, S., Yin, B., Zhang, H., & Betenbaugh, M. (2017) · Biotechnology Journal · doi:10.1002/biot.201600502 · Cited by 48
“A number of mammalian cell lines can be used to generate recombinant antibodies including the widely utilized Chinese Hamster Ovary cells [11].”
BackgroundTakagi, Y., Kikuchi, T., Wada, R., & Ōmasa, T. (2017) · Cytotechnology · doi:10.1007/s10616-017-0066-7 · Cited by 56
“Over the past two decades, recombinant protein productivity has been improved by more than 100-fold (Wurm 2004).”
BackgroundStrategic deployment of C HO expression platforms to deliver Pfizer's Monoclonal Antibody Portfolio
Scarcelli, J. J., Shang, T. Q., Iskra, T., Allen, M. J., & Zhang, L. (2017) · Biotechnology Progress · doi:10.1002/btpr.2493 · Cited by 52
“This results in a collection of cells harboring the linearized expression vector at random chromosomal locations, and at various numbers of copies per cell.(3) Once cell viability has appreciably recovered from selection, cells are single-cell sorted via flow cytometry into static 96-well plates and single cells are a…”
BackgroundAlga‐Made Anti‐Hepatitis B Antibody Binds to Human Fcγ Receptors
Vanier, G., Stelter, S., Vanier, J., Hempel, F., Maier, U. G., Lerouge, P., Ma, J., & Bardor, M. (2018) · Biotechnology Journal · doi:10.1002/biot.201700496 · Cited by 49
Shock wave-induced permeabilization of mammalian cells
Lopez-Marin, L. M., Rivera, A. L., Fernández, F., & Loske, A. M. (2018) · Physics of Life Reviews · doi:10.1016/j.plrev.2018.03.001 · Cited by 50
Stuible, M., Burlacu, A., Perret, S., Brochu, D., Paul‐Roc, B., Baardsnes, J., Loignon, M., Grazzini, E., & Durocher, Y. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.06.307 · Cited by 51
Burnouf, T. (2010) · Vox Sanguinis · doi:10.1111/j.1423-0410.2010.01384.x · Cited by 53
Nakamura, T., & Ōmasa, T. (2015) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2015.01.002 · Cited by 50
Monitoring of autophagy in Chinese hamster ovary cells using flow cytometry
Lee, J. S., & Lee, G. M. (2011) · Methods · doi:10.1016/j.ymeth.2011.11.006 · Cited by 52
Gagnon, M., Nagre, S., Wang, W., & Hiller, G. W. (2018) · Biotechnology Progress · doi:10.1002/btpr.2723 · Cited by 46
“Productivity increases over the past three decades have been significant with fed-batch titers now reaching 5–10 g/L.(1,2) Despite better control of classic metabolic byproducts such as lactate, ammonium, and dissolved carbon dioxide, accumulation of other byproducts still eventually limit cell division and per-cell p…”
BackgroundAdvances in Bioreactor Systems for the Production of Biologicals in Mammalian Cells
Sharma, R., Harrison, S., & Tai, S. (2021) · ChemBioEng Reviews · doi:10.1002/cben.202100022 · Cited by 34
Qiao, J., Oumard, A., Wegloehner, W., & Bode, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.05.012 · Cited by 62
The vesicle-trafficking protein munc18b increases the secretory capacity of mammalian cells
Peng, R., Guetg, C., Tigges, M., & Fussenegger, M. (2009) · Metabolic Engineering · doi:10.1016/j.ymben.2009.08.007 · Cited by 55
Vitamin H-regulated transgene expression in mammalian cells
Weber, W., Bacchus, W., Baba, M. D.-E., & Fussenegger, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm466 · Cited by 48
“Likewise, transgene expression differences also exist between stable and transiently transfected populations, which produce the product protein from expression vector episomes (55, 56 ).”
BackgroundNishimura, K., Segawa, H., Goto, T., Morishita, M., Masago, A., Takahashi, H., Ohmiya, Y., Sakaguchi, T., Asada, M., Imamura, T., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702028200 · Cited by 48
Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones
Yang, W., Zhang, J., Xiao, Y., Li, W., & Wang, T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.858478 · Cited by 51
“In addition, the GS system diminishes the accumulation of ammonia in the medium because overexpressed GS catalyzes the conversion of glutamic acid and ammonia to glutamine (Wurm, 2004).”
BackgroundHammond, S., Swanberg, J. C., Kaplarevic, M., & Lee, K. H. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-67 · Cited by 42
“With over half of all recombinant therapeutic proteins produced in mammalian cell lines, Chinese hamster ovary (CHO) cells remain the predominant production system for glycosylated biopharmaceuticals [1].”
BackgroundDirect analysis of mAb aggregates in mammalian cell culture supernatant
Paul, A. J., Schwab, K., & Hesse, F. (2014) · BMC Biotechnology · doi:10.1186/s12896-014-0099-3 · Cited by 47
“Like other recombinant therapeutic proteins, mAbs are mainly produced in mammalian cells, usually in Chinese hamster ovary (CHO) cells [4].”
Mohan, C., & Lee, G. M. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22781 · Cited by 42
Reexamining opportunities for therapeutic protein production in eukaryotic microorganisms
Matthews, C. B., Wright, C. M., Kuo, A., Colant, N., Westoby, M., & Love, J. C. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26378 · Cited by 59
“…1997; Cereghino & Cregg, 2000; Fleißner & Dersch, 2010; Karas et al., 2015; Karrer, 2000; Miyahara et al., 2013; Penttilä, Nevalainen, Rättö, Salminen, & Knowles, 1987; Potvin & Zhang, 2010; Schaffrath & Breunig, 2000; Singh et al., 2015; Specht et al., 2010; Van Dijk et al., 2000; Wurm, 2004).”
BackgroundMethodLaux, H., Romand, S., Nuciforo, S., Farady, C. J., Tapparel, J. A. R., Büchmann-Møller, S., Sommer, B., Oakeley, E. J., & Bodendorf, U. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26731 · Cited by 48
“2018;115:2530–2540.wileyonlinelibrary.com/journal/bit2530 | © 2018 Wiley Periodicals, Inc. which are correlated with the biological activity and immunogenicity of the product (Fischer et al., 2015; Kim et al., 2012; Wurm, 2004).”
BackgroundZhong, X., Ma, W., Meade, C., Tam, A. S. P., Llewellyn, E., Cornell, R. J., Cote, K., Scarcelli, J. J., Marshall, J. K., Tzvetkova, B., et al. (2018) · Biotechnology Progress · doi:10.1002/btpr.2724 · Cited by 51
Mixing time and kinetic energy measurements in a shaken cylindrical bioreactor
Rodríguez, G., Weheliye, W. H., Anderlei, T., Micheletti, M., Yianneskis, M., & Ducci, A. (2013) · Process Safety and Environmental Protection · doi:10.1016/j.cherd.2013.03.005 · Cited by 47
Nishimiya, D., Mano, T., Miyadai, K., Yoshida, H., & Takahashi, T. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4365-9 · Cited by 57
Ghorbaniaghdam, A., Henry, O., & Jolicœur, M. (2012) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-012-0804-3 · Cited by 47
“, sodium butyrate, pentanoic acid, quinidine and thymidine) [9], or development of efficient fed-batch protocols [10], have allowed to achieve high viable cell densities (10 9 10 cells/mL) and cell-specific productivities for up to 3 weeks [11].”
BackgroundAutomation of cell line development
Lindgren, K., Salmén, A., Lundgren, M., Bylund, L., Ebler, Å., Fäldt, E., Sörvik, L., Fenge, C., & Skoging-Nyberg, U. (2009) · Cytotechnology · doi:10.1007/s10616-009-9187-y · Cited by 47
“In most mammalian expression systems, including the GS system, plasmid DNA is randomly integrated into host cell chromosomes (Wurm 2004) and expression levels are thereby dependent on site of integration.”
BackgroundAmann, T., Schmieder, V., Faustrup Kildegaard, H., Borth, N., & Andersen, M. R. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27101 · Cited by 46
“Nevertheless, genetic instability and intensive cell line generation as well as process development timelines are the major bottleneck of this system (Vcelar, Jadhav, et al., 2018; Vcelar, Melcher, et al., 2018; Wurm, 2004).”
Heterologous protein production using euchromatin-containing expression vectors in mammalian cells
Zboray, K., Sommeregger, W., Bogner, E., Gili, A., Sterovsky, T., Fauland, K., Grabner, B., Stiedl, P., Moll, H. P., Bauer, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv475 · Cited by 53
Tamura, A., Kobayashi, J., Yamato, M., & Okano, T. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.07.006 · Cited by 46
Wong, A. W., Baginski, T. K., & Reilly, D. E. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22749 · Cited by 45
Development of a highly-efficient CHO cell line generation system with engineered SV40E promoter
Fan, L., Kadura, I. A., Krebs, L. E., Larson, J. L., Bowden, D. M., & Frye, C. C. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.08.021 · Cited by 47
Conceptual Design of Micro-Bioreactors and Organ-on-Chips for Studies of Cell Cultures
Mandenius, C. (2018) · Bioengineering · doi:10.3390/bioengineering5030056 · Cited by 47
Baik, J. Y., & Lee, K. H. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26231 · Cited by 50
“Mass recombinant protein production (grams per liter) is a result of significant improvements in many areas, ranging from cell line development to bioprocess manipulations (Jayapal et al., 2007; Wurm, 2004).”
BackgroundMöller, J., Rodríguez, T. H., Müller, J., Arndt, L., Kuchemüller, K. B., Frahm, B., Eibl, R., Eibl, D., & Pörtner, R. (2019) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2019.106693 · Cited by 47
“This ncludes screening studies of medium components ( Torkashvand t al., 2015; Rouiller et al., 2014 ) and the definition of a sta- le and effective process strategy (e.g. fed-batch) ( Wurm, 2004; meiner et al., 2015 ).”
MethodMonoclonal and recombinant antibodies, 30 years after …
Laffly, E., & Sodoyer, R. (2006) · Human Antibodies · doi:10.3233/hab-2005-141-206 · Cited by 57
Development of Transfection and High-Producer Screening Protocols for the CHOK1SV Cell System
Edmonds, M. C. D. L. C., Tellers, M., Chan, C. P., Salmon, P. M., Robinson, D. K., & Markusen, J. F. (2006) · Molecular Biotechnology · doi:10.1385/mb:34:2:179 · Cited by 46
Wu, C., Zhao, S., & Yu, B. (2014) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12116 · Cited by 47
“coli system is a rapid method for expressing proteins but lacks capacity for proper protein folding, assembly and post-translational modification found in eukaryotic systems (Wurm, 2004).”
MethodSimple scale-up of recombinant antibody production using an UCOE containing vector
Boscolo, S., Mion, F., Licciulli, M., Macor, P., Maso, L. D., Brce, M., Antoniou, M. N., Marzari, R., Santoro, C., & Sblattero, D. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.12.005 · Cited by 45
Stable Expression of Chimeric Heavy Chain Antibodies in CHO Cells
Agrawal, V., Slivac, I., Perret, S., Bisson, L., St‐Laurent, G., Murad, Y. M., Zhang, J., & Durocher, Y. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_18 · Cited by 51
General Introduction: Recombinant Protein Production and Purification of Insoluble Proteins
Ferrer‐Miralles, N., Saccardo, P., Corchero, J. L., Xu, Z., & García‐Fruitós, E. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2205-5_1 · Cited by 55
Postiglione, L., Napolitano, S., Pedone, E., Rocca, D. L., Aulicino, F., Santorelli, M., Tumaini, B., Marucci, L., & di Bernardo, D. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00235 · Cited by 46
Process intensification in biologics manufacturing
Strube, J., Ditz, R., Kornecki, M., Huter, M. J., Schmidt, A., Thiess, H., & Zobel‐Roos, S. (2018) · Chemical Engineering and Processing - Process Intensification · doi:10.1016/j.cep.2018.09.022 · Cited by 47
HTS technologies in biopharmaceutical discovery
Wu, G., & Doberstein, S. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.010 · Cited by 56
Rinkenauer, A. C., Vollrath, A., Traeger, A., Tauhardt, L., Kempe, K., Schubert, S., Fischer, D., & Schubert, U. S. (2013) · ACS Combinatorial Science · doi:10.1021/co400025u · Cited by 45
Stansfield, S. H., Allen, E. E., Dinnis, D. M., Racher, A. J., Birch, J. R., & James, D. C. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21263 · Cited by 44
“Whilst systematic optimization of media formulation and rational design of feeding regimes have facilitated increased accumulation of cellular biomass in vitro (Wurm, 2004), cell-engineering strategies to improve qP have proven intractable (Dinnis and James, 2005).”
BackgroundMajumdar, S., Desai, R., Hans, A. K., Dandekar, P. P., & Jain, R. D. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01060-6 · Cited by 50
“There are multiple rounds of amplification required for both techniques after transfection, even though they use different metabolic pathways (nucleotide metabolism for DHFR and glutamine metabolism for GS) [64].”
Link, N., Aubel, C., Kelm, J. M., Marty, R. R., Greber, D., Djonov, V., Bourhis, J., Weber, W., & Fussenegger, M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gnj014 · Cited by 45
“Although several protein therapeutics have been clinically licensed, downstream processing, delivery and pharmacokinetics continue to be major scientific and economic challenges ( 1 ).”
BackgroundInfluentialRaup, A., Stahlschmidt, U., Jérôme, V., Synatschke, C. V., Müller, A. H. E., & Freitag, R. (2016) · Polymers · doi:10.3390/polym8060224 · Cited by 44
“For such applications non-viral agents perform well, reaching transfection efficiencies of >90% together with stable transgene expression for sometimes well over 50 and more cell generations [11,12].”
BackgroundWurm, M. J., & Wurm, F. M. (2021) · Biotechnology Journal · doi:10.1002/biot.202100165 · Cited by 46
Self-citationQuantitative evaluation of mammalian skeletal muscle as a heterologous protein expression system
DiFranco, M., Ñeco, P., Capote, J. C., Meera, P., & Vergara, J. L. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.10.018 · Cited by 44
“Altogether these features make muscle an ideal expression system for applications in the biotechnological industry in which it is imperative to express functional proteins rapidly and eYciently with the proper post-translational modiWcations, including protein folding and glycosylation [6].”
Zhang, X., Stettler, M., Reif, O., Kocourek, A., Dejesus, M., Hacker, D., & Wurm, F. (2008) · New Biotechnology · doi:10.1016/j.nbt.2008.03.001 · Cited by 46
Self-citationMultiplexed expression and screening for recombinant protein production in mammalian cells
Chapple, S. D., Crofts, A. M., Shadbolt, S. P., McCafferty, J., & Dyson, M. R. (2006) · BMC Biotechnology · doi:10.1186/1472-6750-6-49 · Cited by 44
“In order to achieve a high yield of protein for analysis, mammalian expression systems tend to have been based on isolated, high expression stable cell lines [21].”
BackgroundGitzinger, M., Parsons, J., Reski, R., & Fussenegger, M. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00376.x · Cited by 48
The Production of Glycoproteins by Transient Expression in Mammalian Cells
Nettleship, J. E., Rahman-Huq, N., & Owens, R. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-196-3_16 · Cited by 47
Protein‐free fed‐batch culture of non‐GS NS0 cell lines for production of recombinant antibodies
Burky, J. E., Wesson, M. C., Young, A., Farnsworth, S., Dionne, B., Zhu, Y., Hartman, T. E., Qu, L., Zhou, W., & Sauer, P. W. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21060 · Cited by 49
“…mammalian cells have become the dominant expression systems for the production of most protein therapeutics, including antibodies, because of their innate ability to assemble properly configured proteins (i.e., tertiary structure and post-translational modifications) (Wurm, 2004; Yoo et al., 2002).”
Jardon, M. A., Sattha, B., Braasch, K., Leung, A. O., Côté, H. C. F., Butler, M., Gorski, S. M., & Piret, J. M. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.24393 · Cited by 54
Zuker, C. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.016 · Cited by 47
Zang, L., Frenkel, R., Simeone, J., Lanan, M., Byers, M., & Lyubarskaya, Y. (2011) · Analytical Chemistry · doi:10.1021/ac2009492 · Cited by 43
Rouiller, Y., Bielser, J., Brühlmann, D., Jordan, M., Broly, H., & Stettler, M. (2015) · Biotechnology Progress · doi:10.1002/btpr.2186 · Cited by 46
Supported Planar Mammalian Membranes as Models of in Vivo Cell Surface Architectures
Liu, H., Grant, H., Hsu, H.-L., Sorkin, R., Bošković, F., Wuite, G. J. L., & Daniel, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07500 · Cited by 46
Mammalian Cell Culture for Biopharmaceutical Production
Zhang, J. (2014) · ASM Press eBooks · doi:10.1128/9781555816827.ch12 · Cited by 44
Clincke, M., Guédon, E., Yen, F. T., Ogier, V., Roitel, O., & Goergen, J. (2010) · Biotechnology Progress · doi:10.1002/btpr.503 · Cited by 46
“for the production of recombinant proteins because of their established track record, their performances regarding titer and quality of the recombinant protein, and their ability to grow in suspension, in large bioreactors and in complex or defined media.(4,10) Given the variety of potential effects of glycosylation o…”
BackgroundLin, R., Dreyzin, A., Aamodt, K. I., Li, D., Jaminet, S.-C. S., Dudley, A. C., & Melero‐Martin, J. M. (2011) · Blood · doi:10.1182/blood-2011-08-372946 · Cited by 43
Towards the engineering of in vitro systems
Hold, C., & Panke, S. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2009.0110.focus · Cited by 46
Wang, T., & Guo, X. H. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10640-w · Cited by 44
“However, this method is inefficient in transfection, and the probability of screening cells that can express the target protein is very low (Sadikoglou et al. 2014; Wurm 2004; Poulain et al. 2017).”
MethodSchadock‐Hewitt, A. J., & Marcus, R. K. (2013) · Journal of Separation Science · doi:10.1002/jssc.201301205 · Cited by 42
Noh, S. M., Park, J. H., Lim, J., Kim, J., & Lee, G. M. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7876-y · Cited by 50
“Furthermore, the GS system reduces the level of ammonia in culture medium because the overexpressed GS catalyzes the conversion of glutamate and ammonia into glutamine and thereby provides glutamine to cells (Rita Costa et al. 2010; Wurm 2004).”
BackgroundSeparation of antibody monomer-dimer mixtures by frontal analysis
Reck, J. M., Pabst, T. M., Hunter, A. K., & Carta, G. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.04.014 · Cited by 42
“In view of increasing demands to improve downstream process productivity [8,9], there is an interest in exploring alternative chromatographic modalities.”
BackgroundPereira, A. G. M., Walther, J. L., Hollenbach, M., & Young, J. D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700518 · Cited by 46
Poulain, A., Mullick, A., Massie, B., & Durocher, Y. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.03.009 · Cited by 46
Lin, P.-C., Chan, K. F., Kieß, I. A., Tan, J. L., Shahreel, W., Wong, S.-Y., & Song, Z. (2019) · mAbs · doi:10.1080/19420862.2019.1612690 · Cited by 46
“In cell lines with sufficient level of GS, such as CHO cells, addition of the GS inhibitor, MSX allows the selection of productive stable cells.(16,17) Initially, a 2-step selection approach was employed with the first round of 25–50 μM MSX for enhanced stringency and a second round of 100–1000 μM for amplification.”
MethodMolecular analysis of successful cell line selection in transfected GS‐NS0 myeloma cells
Barnes, L. M., Bentley, C. M., Moy, N., & Dickson, A. J. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21119 · Cited by 45
“This is largely due to the ability of mammalian cells to faithfully recreate the correct native tertiary structure of recombinant proteins (Wurm, 2004).”
BackgroundPark, D., Xu, G., Barboza, M., Shah, I. M., Wong, M., Raybould, H., Mills, D. A., & Lebrilla, C. B. (2017) · Glycobiology · doi:10.1093/glycob/cwx041 · Cited by 41
“In addition, understanding the factors that affect glycosylation complement glycan engineering methods that are currently emerging to tune the cell to produce specified glycan patterns (Elliott et al. 2003; Wurm 2004; Du et al. 2009; Hudak et al. 2011; Sackstein 2012).”
BackgroundKozma, B., Hirsch, E., Gergely, S., Párta, L., Pataki, H., & Salgó, A. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.06.070 · Cited by 41
Rajendra, Y., Peery, R. B., & Barnard, G. C. (2016) · Biotechnology Progress · doi:10.1002/btpr.2307 · Cited by 41
“per cell per day) levels of 25–70 p/c/d which are typically only observed in manufacturing cell lines.(1,21,22) The PB pools for mAb2 and BsAb1 were scaled up to 100 mL in a”
Background
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.